Get to know our clinical trials
A study focusing on the ERAP-1-mediated immunopeptidome.
THE PRIMARY OBJECTIVE OF THIS CLINICAL TRIAL IS TO DETERMINE THE SAFETY AND EFFICACY OF THE STUDY DRUG 12GRWD5769, EITHER ALONE OR IN COMBINATION WITH ANOTHER DRUG CALLED LIBTAYO® (CEMIPLIMAB), IN THE TREATMENT OF ADVANCED OR METASTATIC SOLID TUMORS.
Technical Summary
- A PHASE I/II, MODULAR, MULTI-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF GRWD5769 AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER TREATMENTS IN PATIENTS WITH SOLID MALIGNANT TUMORS.
- Code EudraCT: 2023-504845-30-00
- Protocol number: GRWD5769-ST-01
- Promoter: Grey Wolf Therapeutics Limited
- Molecule/Drug: 12GRWD5769
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.